Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of...
BEVERLY Mass. Oct. 12 2018 GLOBE NEWSWIRE Innovation Pharmaceuticals OTCQBIPIX the Company a clinical stage biopharmaceutical company is pleased to provide this update on Brilacidin as a novel...
View ArticleuBiome Appoints Dr. Steven Medwell MD Distinguished Colorectal Surgeon to its...
The leader in microbial genomics appoints renowned surgeon of the Pacific Northwest to its board of medical advisors.SAN FRANCISCO PRWEB October 12 2018 uBiome the leader in microbial genomics...
View ArticleA Thiopurine with Infliximab Might Improve Efficacy in Crohn Disease
Azathioprine use appears to improve pharmacokinetics of infliximab but not among patients with the lowest infliximab concentrations.
View ArticleCelularity Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryCelularity Inc Celularity is a biotechnology company that develops and commercializes therapeutics derived from the placenta for autoimmune and degenerative diseases immunooncology and...
View ArticleInnovent Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryInnovent Biologics Inc Innovent Biologics is a biopharmaceutical company that discovers develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301...
View ArticleCarcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic...
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 Pipeline Review H2 2018SummaryCarcinoembryonic Antigen Related Cell...
View ArticleCrohns Subtype Accurately Predicted through miRNA Molecule
Investigators at Cornell University and the University of North Carolina have just identified that the levels of a single moleculemicroRNA31 miR31can predict whether a patient has subtype 1 or subtype...
View ArticleAmgen launches first biosimilar of bestselling Humira in Europe
Amgen has announced the launch of a proprietary biosimilar version of its bestselling drug Humira adalimumab across all European markets beginning 16 October.Amgevita as the biosimilar is known is the...
View ArticleCelltrion Inc 068270 Financial and Strategic SWOT Analysis Review Report...
Celltrion Inc 068270 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData...
View ArticleKOL Perspectives Selective JAK inhibitors in IBD Report Updated 05012018...
KOL Perspectives Selective JAK inhibitors in IBDSummaryThis KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.The briefing includes analysis of KOL opinion on the following...
View ArticleKOL Perspectives Implementation of the treattotarget approach in IBD Report...
KOL Perspectives Implementation of the treattotarget approach in IBDSummaryThis KOL Insight briefing focuses on KOLs views of implementation of the treattotarget approach in IBD.The briefing includes...
View ArticleKOL Perspectives Views on initial Phase III data for etrolizumab in IBD...
KOL Perspectives Views on initial Phase III data for etrolizumab in IBDSummaryThis KOL Insight briefing focuses on KOL views on etrolizumab Phase III data presented at UEGW 2017 in both Crohn's disease...
View ArticleKOL Perspectives JAK Inhibitor Safety in IBD Report Updated 01052018 Prices...
KOL Perspectives JAK Inhibitor Safety in IBDSummaryThis KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.The briefing includes analysis of KOL opinion on the...
View ArticlePhysician Perspectives 2017 Use of ustekinumab in IBD Report Updated 01022018...
Physician Perspectives 2017 Use of ustekinumab in IBDSummaryThis Physician Perspectives survey focuses on the use of ustekinumab in IBD.UST appears to be the preferred nonTNF biologic for treatment of...
View ArticleuBiome Appoints Dr. Isabel MorenoIndias PhD Senior Researcher of Cellular and...
The leader in microbial genomics appoints leading microbiota and obesity researcher to its board of scientific advisors.SAN FRANCISCO PRWEB October 16 2018 uBiome the leader in microbial genomics...
View ArticleMarker May Help Target Treatments for Crohn's Patients
NewsCrohns disease a chronic inflammatory condition of the intestinal tract has emerged as a global disease with rates steadily increasing over the last 50 years.
View ArticleCrohns Subtype Accurately Predicted through miRNA Molecule...
Crohns Subtype Accurately Predicted through miRNA Molecule httpow.lydjfs30mfNBp pic.twitter.comDM0bhAXwZT
View ArticleResearchers at Cornell and UNC report that levels of a single molecule can...
Researchers at Cornell and UNC report that levels of a single molecule can predict whether a patient has subtype 1 or subtype 2 of crohns disease httpow.lydjfs30mfNBp
View ArticleBiogen and Samsung Bioepis Announce European Launch of IMRALDIadalimumab...
IMRALDITM adalimumab a biosimilar referencing HUMIRAÂ i is the third antiTNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe following BENEPALITM etanercept and...
View ArticleSamsung and Bioepis launch third Humira biosimilar in Europe
Hot on the heels of Amgen Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvies bestselling drug Humira adalimumab in Europe.Like its reference product it is...
View Article